NCT00662870 - Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine | Biotech Hunter

Enrollment

1,941

Participants

Timeline

Start Date

May 31, 2001

Primary Completion Date

January 31, 2004

Study Completion Date

January 31, 2004

Conditions

DiphtheriaTetanusWhooping CoughPolioHaemophilus Influenzae Type b

Interventions

BIOLOGICAL

DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine)

0.5 mL, Intramuscular

BIOLOGICAL

Pentacel: DTaP-IPV/Hib

0.5 mL, Intramuscular

Trial Locations (26)

7240

Jonesboro, AR 72401

14620

Rochester, NY 14620

15213

Pittsburgh, PA 15213

15241

Pittsburgh, PA 15241

19401

Norristown, PA 19401

27514

Chapel Hill, NC 27514

30062

Marietta, GA 30062

32856

Orlando, FL 32856

37664

Kingsport, TN 37664

40004

Bardstown, KY 40004

54449

Marshfield, WI 54449

54601

LaCrosse, WI 54601

60614

Chicago, IL 60614

63044

Bridgeton, MO 63044

71111

Bossier City, LA 71111

72211

Little Rock, AR 72211

72703

Fayetteville, AR 72703

76106

Fort Worth, TX 76107

78205

San Antonio, TX 78205

78758

Austin, TX 78758

80112

Englewood, CO 80112

84604

Provo, UT 84604

92708

Fountain Valley, CA 92708

97201

Portland, OR 97201

99220

Spokane, WA 99220

06360

Norwich, CT 06360